Leverage Shares 2X Long FIX Daily ETF (BATS:FIXX) Sees Large Growth in Short Interest

Leverage Shares 2X Long FIX Daily ETF (BATS:FIXX) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 483 shares, an increase of ? from the August 15th total of 0 shares. Based on an average daily volume of 1,006 shares, the short-interest ratio is presently 0.5 days.

Insider Activity at Leverage Shares 2X Long FIX Daily ETF

In other Leverage Shares 2X Long FIX Daily ETF news, insider Shelia M. Violette sold 2,798 shares of the business’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total value of $46,334.88. Following the transaction, the insider owned 127,771 shares of the company’s stock, valued at approximately $2,115,887.76. The trade was a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jodie Pope Morrison sold 9,845 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $163,033.20. Following the sale, the chief executive officer owned 343,259 shares of the company’s stock, valued at $5,684,369.04. This represents a 2.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 16,615 shares of company stock valued at $275,144 in the last three months.

Leverage Shares 2X Long FIX Daily ETF Stock Performance

Shares of FIXX traded up $0.04 during trading hours on Tuesday, reaching $12.07. The stock had a trading volume of 3,460 shares, compared to its average volume of 2,609. Leverage Shares 2X Long FIX Daily ETF has a 52 week low of $11.21 and a 52 week high of $14.30.

Homology Medicines, Inc was a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare diseases. The company sought to use its proprietary human-derived adeno-associated virus vectors, known as AAVHSCs, to deliver gene therapies in vivo and address the underlying causes of inherited disorders.

Its development programs included HMI-103, an investigational gene therapy for phenylketonuria, as well as earlier programs targeting other rare diseases.